Na. Calcutt et al., TACTILE ALLODYNIA AND FORMALIN HYPERALGESIA IN STREPTOZOTOCIN-DIABETIC RATS - EFFECTS OF INSULIN, ALDOSE REDUCTASE INHIBITION AND LIDOCAINE, Pain, 68(2-3), 1996, pp. 293-299
Rats developed tactile allodynia within days of the onset of diabetes
and which persisted for up to 8 weeks. Allodynia was prevented by insu
lin therapy that maintained normoglycemia while established allodynia
was reversed by insulin therapy and normoglycemia of days but not hour
s duration. Tactile allodynia persisted in diabetic rats that received
enough insulin to maintain normal body and foot weights but remained
hyperglycemic, whereas this therapy was sufficient to correct other ne
rve disorders in diabetic rats, including deficits of sensory and moto
r nerve conduction velocity, nerve blood flow and hyperalgesia during
the formalin test. Treating diabetic rats with the aldose reductase in
hibitor ICI 222155 did not prevent tactile allodynia. Tactile allodyni
a was of similar magnitude in diabetic rats and nerve injured control
rats and diabetes did not alter the magnitude or time course of nerve
injury-induced allodynia. Systemic lidocaine treatment alleviated tact
ile allodynia in nerve injured control rats and both sham-operated and
nerve injured diabetic rats. The streptozotocin-diabetic rat develops
tactile allodynia that appears to be related to prolonged periods of
insulin deficiency or hyperglycemia and which is amenable to treatment
with lidocaine. The model may be of use in investigating the efficacy
of other potential therapeutic agents for treating painful diabetic n
europathy.